Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Bacterial Gastroenteritis Assay Gets CE Mark

NEW YORK (GenomeWeb) — Finnish molecular diagnostics firm Mobidiag said today that its Amplidiag Bacterial GE assay has received CE IVD marking and is now commercially available in Europe.

Amplidiag Bacterial GE is an in vitro diagnostic test indicated to aid in the diagnosis of patients suspected of bacterial gastroenteritis. It uses qPCR to rapidly and qualitatively detect in stool samples eight gastroenteritis-causing bacteria: Campylobacter; Salmonella; Shigella/enteroinvasive Escherichia coli; Yersinia; and enterohemorrhagic, enteropathogenic, enteroaggregative, and enterotoxigenic E. coli.

The test provides same-day results that should be used in conjunction with other clinical and laboratory findings.

CE marking follows the successful completion of a two-center performance evaluation study of 1,235 patient samples and 125 spiked samples, with the test showing an overall sensitivity of 99.0 percent and specificity of 99.9 percent when compared with routine stool culture and independent nucleic acid-based methods, Mobidiag said.

In 2013, Espoo-based Mobidiag successfully completed a three-way merger with Genewave and Amplidiag, solidifying its position in the field of molecular diagnostics.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.